Last reviewed · How we verify

Adjuvant tislelizumab

Tianjin Medical University Cancer Institute and Hospital · Phase 3 active Small molecule

Tislelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.

Tislelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses. Used for Adjuvant treatment of resected non-small cell lung cancer (Phase 3).

At a glance

Generic nameAdjuvant tislelizumab
SponsorTianjin Medical University Cancer Institute and Hospital
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Tislelizumab binds to programmed death receptor 1 (PD-1) on T lymphocytes, preventing engagement with its ligands (PD-L1 and PD-L2) expressed on tumor and immune cells. This blockade reverses T cell exhaustion and enhances cytotoxic T cell proliferation and activation against cancer cells. In the adjuvant setting, it is used post-operatively to reduce recurrence risk in early-stage or resected cancers.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: